282 related articles for article (PubMed ID: 10938881)
1. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
[TBL] [Abstract][Full Text] [Related]
2. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation.
Savi P; Zamboni G; Rescanières O; Herbert JM
Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet-leukocyte interaction and thrombin generation.
Li N; Wallén NH; Savi P; Hérault JP; Herbert JM
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):507-15. PubMed ID: 9819001
[TBL] [Abstract][Full Text] [Related]
4. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
Hoffmann P; Bernat A; Savi P; Herbert JM
J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
Hoffmann P; Bernat A; Savi P; Herbert JM
J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
Ching S; Thoma A; Monkman S; Kelton JG
Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
[TBL] [Abstract][Full Text] [Related]
12. [Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action].
Khaspekova SG; Sirotkina OV; Shimanova IuV; Mazurov AV
Biomed Khim; 2008; 54(3):361-71. PubMed ID: 18712091
[TBL] [Abstract][Full Text] [Related]
13. [Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels].
Khaspekova SG; Ziuriaev IT; Iakushkin VV; Naĭmushin IaA; Sirotkina OV; Zaĭtseva NO; Ruda MIa; Mazurov AV
Biomed Khim; 2014; 60(1):94-108. PubMed ID: 24749250
[TBL] [Abstract][Full Text] [Related]
14. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
15. Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP.
Contreres JO; Dupuy E; Job B; Habib A; Bryckaert M; Rosa JP; Simoneau G; Herbert JM; Savi P; Levy-Toledano S
Br J Haematol; 2003 Feb; 120(4):633-42. PubMed ID: 12588350
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
17. The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
Bernat A; Savi P; Lale A; Hoffmann P; Herbert JM
J Cardiovasc Pharmacol; 1999 Apr; 33(4):573-9. PubMed ID: 10218727
[TBL] [Abstract][Full Text] [Related]
18. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Huang J; Rebello SS; Faul JD; Lucchesi BR
Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
[TBL] [Abstract][Full Text] [Related]
20. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
